Controlled Release Personal Use Arthropod Repellent Formulation. Phase 2. Part 1.
Abstract
The overall objective of Phase II is to bring the prototype sustained release arthropod repellent formulation developed in Phase I to large scale manufacturing stage. This Phase II report details the work conducted during the past eight months for the development of a 12 hour sustained action arthropod repellent formulation. The work culminated in the development of BIOTEK sustained action Formulation 50I which meets virtually all the criteria and requirements of the contract; and the manufacture and submission to USAMRDC of 2,600 samples of the formulation in camouflaged and non-camouflaged labelled containers for evaluation. In addition an EPA Registration Package, a User Training Manual, and a Technical Data Package were prepared and submitted to the Army. Extensive evaluation of BIOTEK Formulation 50I was conducted: 1) in vitro on weanling pig skin 2) in vivo on human volunteers under controlled environments against a variety of mosquitoes; 3) in vivo on human volunteers in field test in Vero Bleach Florida against a variety of mosquitoes; 4) in rabbits against a variety of arthropods; 5) in rabbits to determine toxicity; and 6) for compatability with military materials. Troop Acceptability of the formulation was also determined on human volunteers of military age.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 19, 1986
- Accession Number
- ADB112113
Entities
People
- D. J. Deroo
- E. S. Nuwayser
- N. H. Gay
- P. D. Blaskovich